Peritoneal Surface Malignancy FAQ | Jonathan Greer, M.D.
Jonathan B. Greer, M.D. is an assistant professor of surgery, within the Johns Hopkins Department of Surgery, and oncology, within the gastrointestinal cancer program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. He is the director of the peritoneal surface malignancy program and the associate program director for the complex general surgical oncology fellowship. He is also a member of the gastric cancer center, the sarcoma program, and the neuroendocrine multidisciplinary clinic.
Dr. Greer’s areas of clinical expertise fall mainly within complex general surgical oncology. Within gastrointestinal surgical oncology, Dr. Greer frequently operates on metastatic colorectal cancer, gastric and gastroesophageal cancer, and neuroendocrine tumors. A particular clinical interest is in cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, pseudomyxoma peritonei and tumors of the appendix (both low grade appendiceal mucinous neoplasm or LAMN and high-grade adenocarcinomas or cancers, including goblet cell tumors), colorectal cancer, and gastric cancer. A member of the sarcoma program, Greer operates on retroperitoneal sarcomas and gastrointestinal stromal tumors (GIST). He also has expertise in complex operations for adrenocortical carcinoma and paragangliomas.
Dr. Greer received his undergraduate and medical degrees from Brown University in Providence, Rhode Island. He completed a residency in general surgery at the Massachusetts General Hospital/Harvard Medical School in Boston. He performed a research fellowship in immunology at Memorial Sloan Kettering Cancer Center, in New York, and a clinical fellowship in complex general surgical oncology at the University of Pittsburgh Medical Center.
He is a member of the Association of Academic Surgeons, the American College of Surgeons, the Society for Surgery of the Alimentary Tract, the Trans-Atlantic Retroperitoneal Sarcoma Working Group, the Connective Tissue Oncology Society, and a fellow of the Society of Surgical Oncology (FSSO).